Sareum expects to complete at least one pre-clinical trial this year
Paradigm Biopharmaceuticals completes Zilosul dosing under FDA’s Expanded Access Program
Admedus encouraged by smooth start to new sales model, including first major manufacturing order
Only registered members can use this feature.
© Proactive Investors 2019.
Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority. Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.